StockData
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics (MLTX) stock

MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$12.50−0.37 (-2.87%)

Close on Nov 13, 2026Market cap $1.06BP/E –Yield –

MoonLake Immunotherapeutics cash

Cash and short-term investments held at the end of each period.

MoonLake Immunotherapeutics's cash was $498.50M at Sep 30, 2026. For fiscal 2025 it was $393.97M, down 12.1% from the year before. The highest annual figure on record is $511.01M in fiscal 2023.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$393.97M-12.1%
FY2024Dec 31, 2024$448.03M-12.3%
FY2023Dec 31, 2023$511.01M+608.6%
FY2022Dec 31, 2022$72.12M+797.1%
FY2021Dec 31, 2021$8.04M–
FY2020Dec 31, 2020$0–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$498.50M+31.0%
Q2 FY2026Jun 30, 2026$537.00M+26.3%
Q1 FY2026Mar 31, 2026$357.90M-25.5%
Q4 FY2025Dec 31, 2025$393.97M-12.1%
Q3 FY2025Sep 30, 2025$380.48M-23.0%
Q2 FY2025Jun 30, 2025$425.08M-18.2%
Q1 FY2025Mar 31, 2025$480.13M-12.2%
Q4 FY2024Dec 31, 2024$448.03M-12.3%
Q3 FY2024Sep 30, 2024$493.92M-0.4%
Q2 FY2024Jun 30, 2024$519.80M+3.6%
Q1 FY2024Mar 31, 2024$547.05M+767.7%
Q4 FY2023Dec 31, 2023$511.01M+608.6%
Q3 FY2023Sep 30, 2023$495.98M+494.3%
Q2 FY2023Jun 30, 2023$501.79M+441.3%
Q1 FY2023Mar 31, 2023$63.05M+613.7%
Q4 FY2022Dec 31, 2022$72.12M+797.1%
Q3 FY2022Sep 30, 2022$83.46M+16343.2%
Q2 FY2022Jun 30, 2022$92.71M+4443.4%
Q1 FY2022Mar 31, 2022$8.83M+655.0%
Q4 FY2021Dec 31, 2021$8.04M–
Q3 FY2021Sep 30, 2021$507.56K–
Q2 FY2021Jun 30, 2021$2.04M–
Q1 FY2021Mar 31, 2021$1.17M–
Q4 FY2020Dec 31, 2020$0–

More MoonLake Immunotherapeutics figures

See a number that looks wrong?